PART I Overview We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health. To that end, our experien...
expected 2026-11-05
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001704292-26-000015 | EDGAR | 87K words |
| 2025-02-27 | 2024-12-31 | 0001628280-25-008409 | EDGAR | 86K words |
| 2024-02-27 | 2023-12-31 | 0001628280-24-007235 | EDGAR | 86K words |
| 2023-03-01 | 2022-12-31 | 0001628280-23-005832 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001193125-22-061312 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001193125-21-062279 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001628280-26-053793 | EDGAR | 18K words |
| 2025-11-06 | 2025-09-30 | 0001704292-25-000024 | EDGAR | 18K words |
| 2025-08-07 | 2025-06-30 | 0001628280-25-038548 | EDGAR | 17K words |
| 2025-05-08 | 2025-03-31 | 0001628280-25-023411 | EDGAR | 16K words |
| 2024-11-12 | 2024-09-30 | 0001628280-24-046824 | EDGAR | 17K words |
| 2024-08-06 | 2024-06-30 | 0001628280-24-035231 | EDGAR | 17K words |
| 2024-05-08 | 2024-03-31 | 0001628280-24-021689 | EDGAR | 15K words |
| 2023-11-07 | 2023-09-30 | 0001628280-23-037358 | EDGAR | 22K words |
| 2023-08-07 | 2023-06-30 | 0001628280-23-027773 | EDGAR | 22K words |
| 2023-05-09 | 2023-03-31 | 0001628280-23-016816 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001628280-22-029246 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001628280-22-021975 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001628280-26-053791 | EDGAR | 4K words |
| 2026-02-26 | 0001704292-26-000014 | EDGAR | 5K words |
| 2025-11-06 | 0001704292-25-000023 | EDGAR | 5K words |
| 2025-10-16 | 0001704292-25-000014 | EDGAR | 10K words |
| 2025-08-07 | 0001628280-25-038547 | EDGAR | 5K words |
| 2025-06-18 | 0001628280-25-032099 | EDGAR | 2K words |
| 2025-05-08 | 0001628280-25-023410 | EDGAR | 4K words |
| 2025-02-27 | 0001628280-25-008406 | EDGAR | 5K words |
| 2025-01-03 | 0001628280-25-000261 | EDGAR | 11K words |
| 2024-11-15 | 0001193125-24-259957 | EDGAR | 1K words |
165 total filings indexed. 137 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001704292 |
| Ticker | ZLAB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | E9 |
| Website | https://www.zailaboratory.com |
| Listed | 2017-09-20 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ZLAB (~200 tokens, structured JSON with cryptographic provenance)